ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      59,987.36
      1.27%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Aeterna Zentaris Inc (AEZS)

      7. Aeterna Zentaris Inc (AEZS) News

      AEZS

      Aeterna Zentaris (AEZS)

      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:AEZS
      DateTimeSourceHeadlineSymbolCompany
      09/15/20053:58PMPR Newswire (US)AEterna Zentaris to Present at Upcoming CIBC World Markets Conference in Quebec CityNASDAQ:AEZS
      08/29/200510:03AMPR Newswire (US)AEterna Zentaris Announces Completion of Patient Enrollment for Ozarelix (D-63153) Phase II Trial in Hormone-Dependent ProstateNASDAQ:AEZS
      08/29/20059:01AMPR Newswire (US)Spectrum Announces Completion of Patient Enrollment in Ozarelix Phase II Trial in Patients with Hormone Dependent Prostate CanceNASDAQ:AEZS
      08/03/20058:31AMPR Newswire (US)AEterna Zentaris Reports 2005 Second Quarter Financial and Operating ResultsNASDAQ:AEZS
      07/27/20058:31AMPR Newswire (US)AEterna Zentaris Announces 2005 Second Quarter Financial and Operating Results Conference Call and WebcastNASDAQ:AEZS
      06/09/20058:30AMPR Newswire (US)AEterna Zentaris to Present at BIO 2005 in PhiladelphiaNASDAQ:AEZS
      05/31/20058:31AMPR Newswire (US)AEterna Zentaris' Partner Spectrum Granted IND from FDA to Conduct Phase I/II Clinical Trial with D-63153 in Hormone-Dependent PNASDAQ:AEZS
      05/26/200512:01PMPR Newswire (US)AEterna Zentaris Holds Annual Shareholders' MeetingNASDAQ:AEZS
      05/18/20058:31AMPR Newswire (US)AEterna Zentaris to Hold Annual Shareholders Meeting on May 26 at the Ritz-Carlton Hotel in MontrealNASDAQ:AEZS
      05/17/20055:07PMPR Newswire (US)AEterna Zentaris: An Interim Report of Toxicity and Response From a US National Cancer Institute Phase III Trial in Lung CancerNASDAQ:AEZS
      05/16/20052:40PMPR Newswire (US)AEterna Zentaris' North American Partner Announces Disclosure of Phase II results with Perifosine in prostate cancer at the AmerNASDAQ:AEZS
      05/11/20051:14PMPR Newswire (US)AEterna Zentaris' North American Partner Announces Upcoming Data Presentation on Perifosine at the American Society of ClinicalNASDAQ:AEZS
      05/04/20058:31AMPR Newswire (US)AEterna Zentaris Reports 2005 First Quarter Financial and Operating ResultsNASDAQ:AEZS
      05/02/20056:33PMPR Newswire (US)AEterna Zentaris Subsidiary Atrium Biotechnologies Reports First Quarter 2005 Financial and Operating ResultsNASDAQ:AEZS
      04/27/20058:30AMPR Newswire (US)AEterna Zentaris Announces 2005 First Quarter Financial and Operating Results Conference Call and WebcastNASDAQ:AEZS
      04/21/20058:30AMPR Newswire (US)AEterna Zentaris Expands Therapeutic Approaches in Oncology to Immunotherapeutic VaccinationNASDAQ:AEZS
      04/19/20058:32AMPR Newswire (US)AEterna Zentaris Announces Phase I Positive Results for its Oral Growth Hormone Secretagogue Compound EP-1572NASDAQ:AEZS
      04/14/20058:30AMPR Newswire (US)AEterna Zentaris to Present Exciting New Data on Impavido(R) at the Third World Conference on LeishmaniasisNASDAQ:AEZS
      04/13/20059:16AMPR Newswire (US)AEterna Zentaris Announces Initiation of a European Multi-Center Phase II Trial of D-63153 in Benign Prostate HyperplasiaNASDAQ:AEZS
      04/13/20059:00AMPR Newswire (US)Spectrum Pharmaceuticals Launches Multi-Center, Phase 2 Clinical Trial of SPI-153 in Benign Prostatic HypertrophyNASDAQ:AEZS
      04/11/20059:51AMPR Newswire (US)AEterna Zentaris Announces Initiation of a European Multi-Center Phase II trial of D-63153 in Hormone-Dependent Prostate CancerNASDAQ:AEZS
      04/11/20059:02AMPR Newswire (US)Spectrum Pharmaceuticals Launches, Phase 2 Multicenter, Clinical Trial of SPI-153 in Hormone-Dependent Prostate CancerNASDAQ:AEZS
      04/06/200510:45AMPR Newswire (US)AEterna Zentaris Subsidiary Atrium Biotechnologies Completes Initial Public and Secondary Offering Totalling $75 MillionNASDAQ:AEZS
      04/05/20058:31AMPR Newswire (US)AEterna Zentaris to Present at Three Upcoming Conferences in EuropeNASDAQ:AEZS
      03/30/200511:03AMPR Newswire (US)AEterna Zentaris to Present at Upcoming CIBC World Markets Conference in New York CityNASDAQ:AEZS
      03/29/20059:07PMPR Newswire (US)AEterna Zentaris Subsidiary Atrium Biotechnologies Files Final Prospectus for $75 Million Initial Public OfferingNASDAQ:AEZS
      03/23/20057:31AMPR Newswire (US)AEterna Zentaris Receives First Regulatory Approval for Impavido(R) for Parasitic Skin DiseaseNASDAQ:AEZS
      03/16/20057:31AMPR Newswire (US)AEterna Zentaris Announces Decision to Continue Cetrorelix Development in Benign Prostate Hyperplasia in JapanNASDAQ:AEZS
      03/16/20057:01AMPR Newswire (US)AEterna Zentaris Announces Cetrorelix Development with Solvay Continues with Endometriosis as a Primary IndicationNASDAQ:AEZS
      02/28/20057:31AMPR Newswire (US)AEterna Zentaris Reports 2004 Fourth Quarter and Full-Year Financial and Operating ResultsNASDAQ:AEZS
       Showing the most relevant articles for your search:NASDAQ:AEZS